FDA Watch: Zepto Life Technology Receives FDA Breakthrough Designation for Blood-Based Mold Test
Its FungiFlex assay can make determining the cause of fungal infections vastly more accurate
Already a member? Log in here
FDA-lir
Subscribe today for access to
Articles and Reports
New Enhancing CLIA Act: What Lab Directors Need to Know
The proposal seeks to move any future LDT authority away from the FDA
Already a member? Log in here
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
Lab industry leaders meet with White House on COVID-19 testing
...
Already a member? Log in here
Two commercial labs testing now for COVID-19
...
Already a member? Log in here
FDA Watch: Agency Finalizes CLIA Waiver Guidance for New IV Devices
...
Already a member? Log in here
FDA Watch: Agency to Use EUA Pathway to Clear New Coronavirus Detection Tests
...
Already a member? Log in here
Agency to Use EUA Pathway to Clear New Coronavirus Detection Tests
...
Already a member? Log in here
Lab Companies Scramble to Bring Coronavirus Detection Tests to Market
...
Already a member? Log in here
FDA Watch: Agency Targets Sale of IVD Reagents without Premarket Approval
...
Already a member? Log in here
FDA Watch: Agency Clears the Way for Approval of Blood-Based PSA Test
The U.S. Preventive Services Task Force (USPTF) recommends that men age 55 to 65 consider prostate cancer screening. The reason it doesn’t directly recommend testing for all men in this age group is that current screening methods that rely on detecting high levels of
Already a member? Log in here
FDA Watch: New Process for Simultaneous Review IVD Tests Used in Cancer Drug Trials
Typically, in vitro diagnostic (IVDs) tests used in investigational cancer drug trials require two submissions: one for the IVD test and another for the drug. But on Oct. 9, the FDA issued final guidance allowing companies to submit for simultaneous review for the clinical trial.
Already a member? Log in here
FDA Watch: New NGS Data Guidance May Ease Antiviral Drugs & Companion Test Approvals
A new FDA Technical Specifications document (Tech Doc) lists recommendations for sponsors on use of next generation sequencing data to secure approval of new antiviral drugs and related diagnostic tests providing crucial guidance on six key issues.
Already a member? Log in here